

International Cancer Cluster Showcase 2016

Monday, June 6, 2016; 11:30 a.m. – 4:45 p.m.

San Francisco, Moscone Convention Center, North Building, Rooms 123 & 124

Kindly sponsored by:



11:30 – 12:30 p.m.

REGISTRATION AND LIGHT LUNCH with POSTER SESSION

12:30 – 12:45 p.m.

Opening and Welcome by ICCS Organizing Partners

DNB Healthcare Welcome Note by Allison Hilton, Senior Advisor, Healthcare Corporate Banking
Chiltern Welcome Note by Andrea Cotton-Berry, Executive Director Business Development

12:45 – 1:05 p.m.

Québec, Canada

Exactis
IRICoR
Ovensa

1:05 – 1:25 p.m.

Oslo Cancer Cluster, Norway

Apim Therapeutics
Vaccibody
Targovax

1:25 – 1:45 p.m.

Massachusetts Technology Transfer Center, USA

Siamab Therapeutics
Ontoforce
Empiriko

1:45 – 2:00 p.m.

Takeda Oncology Presentation by Chris Hurff, Director, Business Development
Takeda Pharmaceuticals International Co

2:00 – 2:25 p.m.

NETWORKING BREAK & POSTER SESSION

2:25 – 2:50 p.m.

Dept. of Commerce, USA, Tshanda Kalombo, Senior International Trade Specialist Wistar Institute and Partners, Philadelphia, USA

Atrin Pharmaceuticals
Bantam Pharmaceutical
Feldan Therapeutics

2:50 – 3:10 p.m.

Stanford SPARK, USA

Wong Laboratory: Peptide vaccine to treat Glioblastoma
Alli Laboratory: Small molecule to prevent BRCA1-associated cancers
Sakamoto Laboratory: CREB inhibitors for AML therapy

3:10 – 3:30 p.m.

OBN, United Kingdom

Elasmogen
Magnus Life Science
Opal Oncology

3:30 – 3:40 p.m.

ICCS 2016 Poster Partners

Cancer-Bio-Santé: GamaMabs Pharma
Medicon Valley, Sweden & Denmark

3:40 – 4:45 p.m.

NETWORKING RECEPTION & POSTER SESSION

For more information: www.internationalcancercluster.org



International Cancer Cluster Showcase 2016 – Presenting companies



APIM Therapeutics focuses on the development of first-in-class peptide therapeutics targeting a novel stress-induced therapeutic intervention point in cancer cells. Our lead compound, ATX-101, currently at the pre-CTA/IND stage, shows a broad therapeutic potential in combination with several classes of targeted and chemotherapeutic agents (> 25 different drugs) in multiple cancer indications including bladder and breast cancer, myeloma and others. ATX-101 will enter first-in-man clinical studies in patients with advanced cancer (systemic treatment) and superficial bladder cancer (localized treatment) in late 2016. Founded in 2009 in Trondheim, Norway, as a spin off from the Norwegian Institute of Science and Technology, APIM Therapeutics enjoys strong VC support from a syndicate of investors including Sarsia Seed, NIK III and Birk Venture.

Contact: Kostas Alevizopoulos PhD, CEO; T: + 41 78 752 7002; kalevizo@apimtherapeutics.com
www.apimtherapeutics.com



Atrin Pharmaceuticals LLC, based in Doylestown, PA, is a dynamic biopharmaceutical firm focused on the discovery and development of cancer medications with potential to improve positive treatment results while minimizing the side effects of traditional chemotherapy. Using a groundbreaking drug discovery technology developed and licensed in association with the University of Pennsylvania, Atrin is developing a portfolio of small molecule drug candidates targeting several oncological indications by multiple mechanisms of action. Atrin's business strategy is to take its lead compounds into clinical trials with the ultimate goal of achieving FDA approval for clinical use of its cancer therapeutics either as a monotherapy or in combination with other novel and potent agents. Atrin also plans to use its Atrize™ platform as a tool for personalized medicine.

Contact: Oren Gilad Ph.D., President & CEO; T: +1 215 589 6356; Oren.Gilad@atrinpharma.com
www.atrinpharma.com



Bantam Pharmaceutical, LLC (Bantam) is focused on developing breakthrough targeted therapies that modulate translation of target mRNAs that result in tumor regression. We have identified a set of novel potent inhibitors that target the translation of dysregulated mRNAs that impact multiple cancer signaling pathways critical for tumor growth. Given the central role that these inhibitors play in translation, these inhibitors should be applicable across a broad spectrum of cancer types. Our proof of concept clinical program is currently focused in B-cell malignancies that are currently not addressed by today's therapeutics.

Contact: Mike Luther, PhD, MBA, President and CEO; T: +1 704 460 5330; mluther@bantampharma.com
www.bantampharma.com



Elasmogen is a next-generation biologics company built upon a proprietary, single-domain platform (soloMER) exploiting the power of biologics as drugs but in simpler and more cost efficient formats. SoloMERs are high affinity binding domains, smaller and more stable than antibodies and crucially are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape. Unique to Elasmogen and protected by a portfolio of granted patents, soloMERs are pre-disposed to generating potent neutralizers by binding to novel or cryptic epitopes. Their small size, 1/10th the size of antibodies, and exceptional stability are excellent attributes for site-specific delivery, efficient site-specific conjugation and penetration of solid tumors.

Contact: Dr. Caroline Barelle, MBA, CEO; T: +44 (0) 1224 438545; caroline.barelle@elasmogen.com



Empiriko works at the intersection of biotechnology, clinical diagnostics and bioinformatics, developing technologies for personalized diagnostics and precision patient treatment. Empiriko's patented synthetic liver technology (Biomimiks™) provides a biomimetic platform that assesses the liver's metabolic reaction to drugs, food and environmental agents. The primary application of this technology is to understand the drug/compound metabolites and their toxicity. This platform serves as a foundation for Empiriko's home-based diagnostics device -- Personalized Metabolic Fingerprint™ (PMF) -- designed to optimize dosage, drug-to-drug-interactions, drug-to-food-interactions and toxicity for at-risk patients in real-time, using a single drop of blood. This technology could also increase patient compliance, especially important for high-risk patients, and enables physicians to make improved clinical decisions at the point of care, resulting in better patient outcomes.

Contact: Pam Randhawa, CEO; T: +1 617 755 8678; pam.randhawa@empiriko.com
www.empiriko.com

International Cancer Cluster Showcase 2016 – Presenting companies



E X A C T I S

Exactis Innovation is a non-profit organization with the vision to improve cancer survivorship through innovative research. Our mission is to become a leading international network of excellence for next generation biomarker-led translational and clinical research that will accelerate drug development, increase treatment options for cancer patients and achieve cost-savings to the healthcare system.

Contact: Richard Fajzel, Vice President Business Development; T: +1 418 781 0500; rfajzel@exactis.ca
www.exactis.ca



Feldan Therapeutics has developed a protein-based platform for direct delivery of proteins inside cells called the Feldan Shuttle. The company also possesses a recombinant protein production unit with an expertise in the manufacture of high-quality therapeutic proteins, such as nucleases and transcription factors. This fully integrated structure has led to a business model focused on the in-house development of gene-modified cell therapies and the co-development of other applications with corporate and academic partners. These distinct characteristics coupled with a deep scientific knowledge will allow Feldan to become the prime developer of gene modified cell therapies in Canada.

Contact: Francois-Thomas Michaud, CEO; T: +1 418 872 7277 x337; ftmichaud@feldan.com
www.feldan.com



GamaMabs Pharma is a French biotechnology company developing optimized monoclonal antibodies in cancer. The company's lead project is the first-in-class monoclonal antibody GM102, currently entering the clinic. GM102 targets the anti-Mullerian human receptor II (AMHRII/MISRII), an unaddressed specific target in gynecological cancers. These cancers are responsible for over 130,000 deaths every year in Europe and the United States (Source: Globoscan 2012/WHO). GamaMabs Pharma also develops additional low-fucose EMABling® antibodies (license granted by LFB) with increased tumor cell killing properties through the activation of immune system cells. The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.

Contact: Stephane Degove, CEO; T: +33 531616069; sdegove@gamamabs.com
www.gamamabs.com



IRICoR, the Institute for Research in Immunology and Cancer – Commercialization of Research, is a not-for-profit drug discovery and commercialization center created in 2008 and based at Université de Montréal (UdeM). IRICoR is a fully integrated center under a single roof, with one of the largest academia-based industry-experienced medicinal chemistry groups in Canada. Our mission is to rapidly translate highly innovative and commercially promising projects from IRIC/UdeM/collaborating centers into high-value novel therapies mainly in oncology and immunology. We support and invest in selected projects to rapidly transition them from academia to the market with the best targeted partners for development and financing.

Contact: Nadine Beauger, Vice-President, Scientific Liaison; T: +1 514 343 6111 ext. 0315;
nadine.beauger@iricor.ca
www.iricor.ca



Amongst our various programs, **Magnus Life Science** is focused on developing a novel tumor immune microenvironment modulator. The program is pursuing a new approach to the treatment of solid tumors based on an understanding of the interplay between the immune system and the tumor micro-environment. The approach targets a key cell surface receptor involved in modulating lymphocyte response to the tumor. Recent studies have demonstrated pre-clinical proof of concept for the approach in vivo where dramatic tumor ablation was seen in two separate and aggressive cancer models. Magnus Life Science is finalizing a structure-function based small molecule drug discovery and optimization program that has yielded potent series of proprietary compounds. Clinical strategy will initially focus on combination studies with leading cancer immunotherapies in solid tumors such as renal and lung.

Contact: Dr. Mark Lees, Director, Portfolio Management; T: +44 (0) 7866 516 236;
mlees@magnuslifescience.co.uk
www.magnuslifescience.co.uk

International Cancer Cluster Showcase 2016 – Presenting companies



ONTOFORCE is a life sciences and health IT company specialized in linked data technology with offices in Belgium and Cambridge, US. Their user-friendly online search application, DISCOVER, is driven by semantic technology building intelligent links across multiple heterogeneous internal, third party and external data sources. DISCOVER provides high accuracy and easy access to real time information beyond traditional resources and data providers. Everybody becomes a data scientist using DISCOVER, resulting in significant time-savings, better decision making and more innovation in various fields such as research and business development.

Contact: Hans Constandt, Founder & CEO; T: +32 (0) 477566102; hans@ontoforce.com
www.ontoforce.com



Opal Oncology is a Cambridge UK drug discovery company driven to seeking out commercially viable anti-cancer therapies in high-impact orphan indications, which have been failed by existing drugs. Their vision is to discover and in-license early stage small molecule anti-cancer projects, which they will advance to IND. Working on a virtualized biotech model, they are able to access the best expertise, research and partners from academic groups, charitable organizations and other biotech companies. Research to date has shown Opal Oncology's lead program has assets proven to be more effective at killing a broader range of common cancer cell lines than current approved Glioblastoma Multiforme treatments, validating the possibility of increasing life expectancy over existing therapies for this challenging cancer indication.

Contact: Sunil Shah, CEO; T: +44 (0)7887 574787; sunil@o2h.com
www.opalonc.com



Ovensa Inc. is a Canadian, preclinical stage company that capitalizes on its proprietary TRIOZAN™ Nanomedicine Delivery Platform, with mucosal and brain-barrier crossing properties, to generate advanced, multi-combination nanotherapeutics, that enhance the bioavailability and the targeted intracellular uptake of small molecules and biologics through oral and other routes of administration. Ovensa focuses in oncology and neurodegenerative diseases where its platform can significantly improve therapeutic outcomes

Contact: Stéphane Gagné, President and CEO; T: +1 514 402 1764; sgagne@ovensa.com
www.ovensa.com



Siamab Therapeutics, Inc. is developing therapies targeting cancers that express abnormal carbohydrates. These highly cancer specific, tumor associated carbohydrate antigens (TACAs) are present in the majority of solid tumors including ovarian, pancreatic, prostate, colon, gastric, and breast cancers, and are exploited by tumor cells to suppress innate immune function, enable tissue invasion and metastasis, resist chemotherapy, and promote a stem-cell phenotype. Siamab has developed a technology platform that enables the discovery of large numbers of highly specific, high affinity anti-TACA therapeutic antibodies. Siamab antibodies, formatted as antibody drug conjugates (ADCs) have shown safety and efficacy both in vitro and in vivo and our lead program is in late preclinical development and we expect to initiate GMP manufacturing in 2017.

Contact: Jeff Behrens, President & CEO; T: +1 617 500 3455; Jeff@siamab.com
www.siamab.com

SPARK

AT STANFORD



Stanford SPARK: The Alli Laboratory at Wake Forest School of Medicine and the SPARK at Stanford program are developing a cancer chemoprevention agent for individuals who inherit a deleterious mutation in the BRCA1 gene. The agent is within a novel class of compounds termed DNA repair-activating agents, and in vitro and in vivo data provide evidence that the drug reduces malignant properties associated with BRCA1-mediated tumorigenesis with minimal toxicity. Current efforts aim to manufacture the drug and conduct a clinical trial.

Contact: Elizabeth Alli, PhD, Assistant Professor, Department of Cancer Biology; T: +1 336 713 0059;
ealli@wakehealth.edu
www.wakehealth.edu

International Cancer Cluster Showcase 2016 – Presenting companies

Stanford SPARK, The Wong Laboratory: We have developed technologies to improve a peptide vaccine to treat glioblastoma. EGFRvIII is an excellent target for precision medicine: a highly expressed, tumor specific alteration of the EGF receptor that is constitutively active and a marker for cancer stem cells. An anti-tumor peptide vaccine approach is an ideal off the shelf approach for treating glioblastoma. A randomized Phase II study for recurrent glioblastoma received Breakthrough Therapy Designation from the FDA. While a Phase III trial for newly diagnosed patients did not show superiority both control and vaccine arm significantly outperformed any previous study. Interestingly, the original peptide sequence was never optimized for an anti-tumor response. Using the crystal structure to guide our studies, we explored multiple sequence variations in animal tumor regression experiments and identified several candidates that significantly increased the survival rate over the original vaccine. These candidates also show an increase in several immunologic parameters. We are poised to begin work on a Phase I trial.

Contact: Albert Wong, M.D., Professor Department of Neurosurgery and Cancer Biology Program;
T: +1 650 736 4220; ajwong@stanford.edu
www.med.stanford.edu

Stanford SPARK: The Sakamoto laboratory at Stanford University is developing small molecules and peptides to target the cyclic AMP Response Element Binding Protein (CREB) function for treatment of hematologic malignancies. CREB is a transcription factor that is over-expressed in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and is associated with a worse prognosis. Knockdown of CREB inhibits growth of AML cells but does not kill normal bone marrow stem cells. Small molecules that inhibit interaction of CREB with its binding partner and histone acetyltransferase CBP (CREB Binding Protein) inhibits leukemia progression in vivo. Structure Activity Relationship studies and small molecule screening approaches are being used to develop a lead compound for treatment of hematologic malignancies, including AML and MDS.

Contact: Kathleen M. Sakamoto, M.D., Ph.D., Shelagh Galligan Professor, Division of Hematology/Oncology;
T: +1 650 725 7126; kmsakamo@stanford.edu
www.sakamotolab.com

Targovax is a clinical stage immuno-oncology company dedicated to the development of targeted immunotherapy treatments for cancer patients. Targovax are developing two complementary and highly targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. Both treatment approaches harness the patient's own immune system to fight the cancer. Targovax's lead peptide-based targeted immunotherapy, TG01, is currently in a phase II clinical study in resected pancreatic cancer. Encouraging interim 1 year overall survival data showed that 14 out of 15 evaluable patients were still alive after one year. This contrasts favorably with a historical 1-year overall survival rate of only 75%. Targovax's lead adenoviral product, ONCOS-102, has also successfully completed Phase I clinical studies and confirmed its tumor specific and systemic activity. ONCOS-102 will enter further clinical studies in the near future for the treatment of solid tumors such as melanoma, malignant pleural mesothelioma, and ovarian cancer.

Contact: Peter Skorpil, Ph.D., MBA, VP Business Development; T: +47 928 28 259;
peter.skorpil@targovax.com
www.targovax.com

Vaccibody is a clinical stage biotech company that uses proprietary, patent-protected Vaccibody vaccines, specifically tailored to induce a rapid, strong and long lasting immune response. Vaccibody is developing vaccines containing what are known as "neoantigens"—genetic fingerprints generated by tumors as they mutate. By vaccinating with "neo-epitopes" in a DNA version of a Vaccibody vaccine, Vaccibody is aiming at specifically activating the neoantigen-specific T cells to attack the tumor. The backbone in the Vaccibody "neoantigen" vaccine is a proprietary DNA construct that potentiates vaccines by targeting the antigen to antigen-presenting cells. This has been produced under GMP and data reported from clinical phase I shows the DNA construct is safe and well tolerated. Vaccibody is also developing a vaccine for patients with HPV induced high-grade cervical intraepithelial neoplasia (CIN 2/3). This vaccine candidate (VB10.16) is currently in clinical phase I/IIa trial. We are seeking to explore the full potential of the Vaccibody vaccine technology and are looking for partners both for our "neoantigen" programs as well as for VB10.16.

Contact: Martin Bonde, PhD, BComm, CEO; T: +45 2025 3560; mbonde@vaccibody.com
www.vaccibody.com

SPARK

AT STANFORD

SPARK

AT STANFORD

targovax

vaccibody

International Cancer Cluster Showcase 2016 – Organizing Partners

Massachusetts Technology Transfer Center - Massachusetts' unique ecosystem of leading research institutions, supporting organizations, and investor community spurs the creation of numerous new companies every year. Massachusetts' cancer expertise is maintained by cutting edge research at multiple institutions including the Dana-Farber Cancer Institute and the David Koch Institute for Integrative Cancer Research at MIT. Many of the newly formed companies in the Commonwealth focus on cancer diagnostics and treatment. The Massachusetts Technology Transfer Center is a non-profit organization that supports technology transfer activities from public and private research institutions to companies in Massachusetts. To achieve this goal, the Center works with technology transfer offices at Massachusetts research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth.

Contacts: Abigail Barrow, abarrow@umassp.edu; Christa Bleyleben, cbleyleben@massglobalpartners.com; www.mttc.org

Identify the right patients for the right clinical trials! Our mission is to become a network of internationally renowned excellence in translational and clinical research based on new-generation biomarkers that contribute to the development of drugs, increase treatment options for cancer patients and thus achieve cost savings in the health care system. By building prospectively extremely basic clinical and molecular data of cancer patients, and across Canada, **Exactis** is able to rapidly identify patients for clinical trials based on biomarkers. The Center of Excellence in Innovation Exactis Precision Therapeutics is a non-profit organization. We believe in improving the chances of cancer survival through access to innovative personalized care.

Contact: Richard Cloutier, Richard.cloutier@cqvb.qc.ca; www.exactis.ca

The Wistar Institute is the nation's first independent institution devoted to medical research and training. The Wistar Institute has evolved from its beginnings as an anatomical teaching museum to its present-day status as an international leader in basic biomedical research. In 1972, The Wistar Institute was designated a National Cancer Institute Cancer Center in basic research, a distinction it holds to this day. Wistar discoveries have led to the development of vaccines for rabies, rubella, and rotavirus, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.

Contact: Heather Steinman, HSteinman@Wistar.org; www.wistar.org

Oslo Cancer Cluster is an oncology focused research and industry cluster. Organized as non-profit member organization Oslo Cancer Cluster is dedicated to accelerate the development of new cancer treatments. The 75+ members represent the entire R&D value chain and include academic research institutes, university hospitals, biotech, investors, and international Pharma companies. The cluster's growing pipeline comprises innovative therapeutics and diagnostics including novel cancer immunotherapies in preclinical and clinical development.

Contact: Jutta Heix, jh@oslocancercluster.no; www.oslocancercluster.no

OBN is the Membership organization supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors. Our 360-plus Member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland benefiting from our networking, partnering, purchasing, advising and advocacy activities.

Contact: Neil.Halliday@obn.org.uk; www.obn.org.uk

The **Stanford SPARK program** was created nine years ago with the overarching goal of translating Stanford's biomedical research discoveries into therapeutics that will positively impact patient care and the health of our society. SPARK is a partnership between Stanford University and volunteers from the local biotechnology, pharmaceutical, and health care investment industries. SPARK's mission is three-fold: first, to help academic investigators overcome the obstacles intrinsic to moving research discoveries from bench to bedside; second, to educate faculty, postdoctoral fellows, and graduate students regarding the translational research process so that development of promising new discoveries becomes second nature at our institution; third, to promote efficient, cost-effective, and innovative approaches to discovery and development. As a non-profit program, SPARK can give special consideration to development projects that are generally neglected by the for-profit sector.

Contact: Nancy Anne Federspiel, nfeder@stanford.edu; www.med.stanford.edu



International Cancer Cluster Showcase 2016 – Poster Partners

mediconValley

Medicon Valley is the leading life science cluster in Scandinavia with substantial focus on oncology innovation and research. The cluster is home to several leading companies and highly innovative and result generating cancer research centers such as the CREATE health, Lund University Cancer Center and the Sino Danish Breast Cancer Research Centre, Rigshospitalet in Copenhagen and Danish Cancer Society Research Centre. The unique collaborative culture driving the innovation in Medicon Valley, combined with a resolute focus and leading expertise, makes the cluster an invaluable place in which to develop the cure for cancer.



A unique and broad approach throughout the continuum of cancer **Cancer-Bio-Santé Cluster**, located in Toulouse, is the French cluster in France fully dedicated to the fight against Cancer, throughout a broad continuum approach involving prevention, diagnostics, therapeutics and patient monitoring. CBS supports companies from the Midi Pyrénées and Limousin regions, which develop innovative products in the fields of food & Health, Diagnostics, Biomarkers, Nanotechnologies, Medical Devices, Immunotherapy, Therapeutics, Biotechnologies and Telemedicine. The mission of the Cancer-Bio-Santé cluster is to support companies to develop innovative products by synergizing public and private research and clinical research actors.

Special thanks to our sponsors!



NOTES: